Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04857307 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy
A Phase 1 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04857307 is a Phase 1 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 14 participants.
The verdict
NCT04857307, a Phase 1 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the pharmacokinetics (PK), tolerability, and safety of Staccato alprazolam in adolescent study participants with epilepsy following single-dose administration.
Interventions
- DRUG Alprazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2022-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857307
The ClinicalTrials.gov registry entry for NCT04857307 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alprazolam is the first listed.
NCT04857307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04857307 about?
NCT04857307 is a clinical study titled "A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy". The purpose of the study is to assess the pharmacokinetics (PK), tolerability, and safety of Staccato alprazolam in adolescent study participants with epilepsy following single-dose administration.
What is the current status of trial NCT04857307?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-04-28. Estimated completion is 2022-04-05.
What interventions are being tested in trial NCT04857307?
The interventions under investigation include: Alprazolam (DRUG).
Who is sponsoring clinical trial NCT04857307?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.